STOCK TITAN

Danaher Corporation - $DHR STOCK NEWS

Welcome to our dedicated page for Danaher Corporation news (Ticker: $DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Danaher Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Danaher Corporation's position in the market.

Rhea-AI Summary
Danaher Corporation appoints Christopher Riley as Executive Vice President of its Biotechnology business, effective January 1, 2024. Riley, currently Vice President and Group Executive of Danaher's Life Sciences company, has a strong track record of delivering results and will report to President and CEO Rainer Blair.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.74%
Tags
management
-
Rhea-AI Summary
Danaher Corporation announces Q3 2023 results, with net earnings of $1.1 billion and revenues of $6.9 billion. Non-GAAP adjusted diluted net earnings per common share were $2.02. The company expects non-GAAP base business core revenue to be down mid-single digits YoY for Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags
-
Rhea-AI Summary
Integrated DNA Technologies (IDT) completes its new Therapeutic Oligonucleotide Manufacturing facility in Coralville, Iowa, marking its entrance into the therapeutics space. The facility will produce cGMP cell and gene therapy reagents and support researchers in transitioning from the lab to therapeutic development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
none
Rhea-AI Summary
Abcam files investor presentation and letter to shareholders regarding proposed sale to Danaher Corporation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
none
-
Rhea-AI Summary
Abcam plc files scheme circular for acquisition by Danaher Corporation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.04%
Tags
-
Rhea-AI Summary
Danaher Corporation completes spin-off of Veralto Corporation, creating opportunities for both companies to deliver value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Battery Ventures creates new laboratory-automation platform through acquisitions of Skalar Analytical, PromoChrom Technologies, and LCTech.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
none
-
Rhea-AI Summary
Danaher Corporation will webcast its quarterly earnings conference call for the third quarter 2023 on October 24, 2023 at 8:00 a.m. ET. The company will discuss its financial performance and future expectations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
-
Rhea-AI Summary
Danaher Corporation announces agreement to provide Cepheid's TB test cartridges at cost to the Global Fund and less-developed countries
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
none
News
Rhea-AI Summary
Danaher Corporation approves regular quarterly cash dividend of $0.27 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
dividends
Danaher Corporation

NYSE:DHR

DHR Rankings

DHR Stock Data

184.84B
659.36M
10.76%
81.69%
0.86%
Instruments and Related Products Manufacturing for Measuring, Displaying, and Controlling Industrial Process Variables
Manufacturing
Link
United States of America
WASHINGTON

About DHR

Danaher Corporation is an American globally diversified conglomerate founded by brothers Stephen and Mitchell Rales in 1984. Headquartered in Washington, D.C., the company designs, manufactures, and markets medical, industrial, and commercial products and services.